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Introduction
Long chain of non-coding RNAs (LncRNAs), a class of non-coding transcripts longer than 200 bps, are involved in regulating gene expression on a variety of levels including epigenetic, transcriptional and post-transcriptional regulations [1] [2] [3] . Recently, lncRNAs have attracted a broad attention for their function in X-chromosome silence, genomic imprinting and chromatin modification, transcription activation, transcription interference and nuclear transport, among others. Previous studies suggested an important role of lncRNAs in tumor progression [4] . For example, high expression of lncRNAs, such as BANCR, LSINCT5, HULC are closely related to the high incidence of melanoma, breast cancer and liver cancer [5] [6] [7] . However, the role of lncRNAs in lung adenocarcinoma remains largely unknown.
In our previous study, we screened human lung adenocarcinoma and non-cancerous tissues by Arraystar lncRNA gene chip and found that a group of lncRNAs are differently expressed in cancer and adjacent normal tissues [8] . In the present study, we verified our findings by comparing the expression of lncRNAs in cancer tissues and adjacent normal tissues derived from 40 patients with lung adenocarcinoma. We found a lncRNA, named ZXF2 (SEQ_ID: AA311918, located on chromosome 8, loci 8q24.2) had an average of 8.879 fold higher expression in lung adenocarcinoma tissues than that in non-cancerous tissues. Further analysis revealed that overexpression of ZXF2 was correlated with high lymph node metastasis and poor prognosis. Further study on the molecular mechanisms underlying ZXF2 meditated tumor progression, we found that siRNA mediated suppression of ZXF2 led to cell cycle arrest and inhibition of cell proliferation, migration and invasion through regulating c-Myc, a strong proto-oncogene which is located adjacent to ZXF2 in chromosome loci 8q24.2, a common location for multiple tumors.
Materials and Methods

Patients and specimens
Forty pairs of samples were obtained from patients with lung adenocarcinoma, who were treated in the Department of Cardiothoracic Surgery, Zhongnan Hospital, Wuhan University. Average length of tumor tissue was 2.4cm, average age of patients was 62 years old. All of the non-cancerous tissues were more than 5 cm away from tumor tissues. These patients underwent surgical resection of tumors and were pathologically diagnosed with lung adenocarcinoma (stage I, II and III) between June 2010 and June 2012. The clinicopathological parameters of the patients were summarized in Table 1 . None of the patients received chemotherapy and radiotherapy before surgery. The study was approved by The Human Research Ethics Committee of Wuhan University.
Real-time RT-PCR
Quantitative Real-time RT-PCR (qRT-PCR) was performed using FastStart Universal SYBR Green Master (Rox) kit on an ABI 7300 real time PCR System. ACTIN was used as internal control. The relative expression levels of ZXF2 were determined by normalizing expression of ZXF2 to that of ACTIN. ZXF2 primer sequence, sense: 5'-CAC CCA GGT CAG AGA AAG CA-3'; antisense: 5'-TGG AAG GGA CAC TAG AAG AAG AAT-3'. ACTIN primer sequence, sense: 5'-CAC CCA GCA CAA TGA AGA TCA AGA T-3'; antisense: 5'-CCA GTT TTT AAA TCC TGA GTC AAG C-3'. We defined positive expression of ZXF2 as a greater than 2 fold increase in carcinoma tissues than that in non-cancerous tissues.
ZXF2 siRNA transfection
Three siRNA sequences specifically against ZXF2 and control scramble siRNA (siRNA-NC, as a negative control) were synthesized from Gene-pharma (shanghai, China). SiRNA against ZXF2 and scramble siRNA were then transfected by lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). The efficiency of siRNAs was determined by comparing expression of ZXF2 in siRNA treated cells to that in siRNA-NC treated cells. 
Cell proliferation assay by CCK-8
To determine the effect of ZXF2 on cell proliferation, A549 cells transfected with siRNA-ZXF2 were seeded into 96well plates at a density of 3×10 3 cells/well and incubated for 24h, 48h, 72h, and 96h, respectively. SiRNA-NC treatment was used as a negative control. The effect of ZXF2 on cell proliferation was determined by using cell count kit-8 (CCK-8) (Boster,China) as described previously [9] . Briefly, at the end of incubation, 10 µl of CCK-8 solution was added to each well. Four hours later, the number of viable cells was determined by the absorbance of water-soluble formazan at 460 nm using a FlexStation 3 plate reader (Molecular Devices, CA).
In vitro migration and invasion assays
The procedure was described previously [10] . In brief, in vitro cell migration was examined in Boyden chamber system. A549 cells (1×10 5 ) treated with either siRNA against ZXF2 or siRNA-NC suspended in serum-free medium were added to the upper chamber (6.5-mm diameter, 8-μm pore size, Corning), and the chamber was placed in 24-well dishes. Migration was permitted for 24 h, and cells were then fixed with 4% formaldehyde.
In vitro cell invasion assays were conducted using a Boyden chamber (2×10 5 cells per well) with Matrigel-coated invasion inserts (BD Biosciences, 8 µm pore membranes) placed according to the manufacturer's instructions.
Twenty-four hours after incubation, trans- Table 1 . Relative ZXF2 level in tumor tissues of the patients with lung cancers migrating cells on the underside of the inserts were fixed with 4% formaldehyde and stained with 4',6-diamidino-2-phenylindole (DAPI). Fluorescent images of five random fields were acquired, the average number of cells per field was calculated and presented.
Western blot
Protein was extracted from cells by RIPA buffer. The protein lysate was separated by 12.5% SDS-PAGE, and electrophoretically transferred to a PVDF (polivinylidene difluoride) membrane (Roche). Then, the membrane was probed with antibodies against c-myc (Proteintech), e-cadherin (Proteintech) and GAPDH (as an internal control) (Proteintech); and horseradish peroxidase-conjugated secondary antibodies (Pierce Biotechnology, Rockford, IL). The chemiluminescence of proteins on PVDF membranes was detected with ECL Plus kit (Pierce).
Cell cycle and apoptosis assay
The cells were harvested after transfection with siRNA against ZXF2 and siRNA-NC for 48 hours. Then the cells were subjected to either cell cycle detection kit (Beyotime, China) or cell apoptosis detection kit (Sungene, China) by using a FACS Calibur instrument (Becton Dickinson, CA, USA).
Statistical analysis
Statistical analyses were conducted using SPSS17.0 software. Student's T test was used for paired data. Composition ratio was used to describe counting data. Chi-square test was used for clinical data analysis. Survival curves were plotted by Kaplan-Meier method and log-rank method. P values of ﹤0.05 were considered statistically significant.
Results
ZXF2 overexpresses in lung adenocarcinoma and the expression is negatively correlated with patients' prognosis
We collected cancer and adjacent normal tissues from 40 patients with lung adenocarcinoma and analyzed the expression of ZXF2 in these samples by qRT-PCR. As shown in Fig. 1A and Table 1 , the expression of ZXF2 in tumor tissue is significantly higher than that in adjacent normal tissues (with a mean increase of 7.23 fold, and a median increase of 5.56 fold). In addition, 27 out of 40 cancer tissues (67.5%) had a 2 fold or higher expression of ZXF2 than that in adjacent non-cancerous tissues (p<0.05). This result confirm our previous observation [8] . (Fig. 1B,  p<0 .01). Taken together, this analysis suggested that high expression of ZXF2 was closely correlated with tumor progression in human lung adenocarcinoma. Yang 
ZXF2 regulates cell cycle, proliferation, migration and invasion of lung cancer cells
In order to elucidate molecular mechanism of ZXF2 in promoting lung cancer development, in vitro cell culture experiments were employed. We first tested the expression ZXF2 in A549, H1299, and H1395 lung adenocarcinoma cell lines by qRT-PCR. As shown in Fig. 2, A549 had highest level of ZXF2 among these cell lines (P<0.01, Fig.2A ). Because A549 was reported to be a high invasive and metastatic lung adenocarcinoma cell line [11] , we chose it in the following experiments. We used siRNA technology to specifically knockdown the endogenous ZXF2 in A549 cells.
Three different RNA interference sequences were originally designed in this study: siRNA-65: 5'-GCU GUU GGA UGU CAC ACA CTT-3'; siRNA-231: 5'-CCC AAA UCU UCC UUC AAA UTT-3'; siRNA-295: 5'-GCC UGU CCU CAA UCC CUA UTT-3'. Compared to negative control siRNA (5'-UUC UCC GAA CGU GUC ACG UTT-3'), transfection of siRNA-65 resulted in highest inhibitory efficiency among these three siRNAs, which led to about 70% reduction of ZXF2 expression, (Fig. 2B) . Based on this result, we selected siRNA-65 in the following experiments to test the functions of ZXF2 in lung cancer cells.
We first tested the effect of siRNA on cell proliferation. We found that siRNA-ZXF2 treatment significantly suppressed proliferation at different time points compared to A549 cells treated with siRNA-NC (P<0.01, Fig. 3A) . In order to elucidate the mechanisms underlying siRNA-ZXF2 induced proliferation suppression, we investigated whether siRNA-ZXF2 treatment can induce cell death by flow cytometry. Interestingly, we did not observe obvious apoptosis in A549 cells treated with siRNA-ZXF2 (Fig. 3B-3D ).
Then, we tested whether knockdown of ZXF2 can affect cell cycle. Flow cytometry analyses of cell cycle distribution revealed that reduction of ZXF2 resulted in a significant increase of cell number in the G 0 /G 1 phase and a slight reduction in S and G 2 /M phases compared with cells transfected with siRNA-NC as a control. (P<0.01, Fig.4A-C, Table 3 ), indicating G 0 /G 1 arrest might contribute to proliferation inhibition by siRNA-ZXF2. We further examined the changes of several cell cycle related proteins that are known involved in lung cancers. The results shown that knockdown of ZXF2 did not change the expression of p21, Cyclin B1, but resulted in down regulation of Cyclin D1, whereas transfection of siRNA-NC had no effects on these proteins (Fig. 4D) . Given the fact that Cyclin D1 plays an important role in the proliferation and progression of lung cancers [12] , the Western blot results were consistent with the cell cycle distribution. We tested the potential function of ZXF2 on tumor cell migration and invasion. Boyden chamber transwell assay was used to determine cell migration and invasion capacities. After transfected with siRNA-ZXF2, both migration and invasion capacities were significantly inhibited as compared to those of cells treated with siRNA-NC. Specifically, the mean number of migrated cells per view in siRNA-ZXF2 treated group was 214.60 ± 11.89, while that in siRNA-NC treated group was 690.40 ± 11.54(more than 3-fold increase) (P<0.01). In addition, we observed a more than 10-fold reduction in invasive ability of the cells treated with siRNA-ZXF2 (57.80 ± 4.73 cells/view in siRNA-ZXF2 treated group vs 628.20 ± 7.08 cells/view in siRNA-NC treated group; P<0.01, Fig. 5A-F) .
Knockdown of ZXF2 leads to inhibition of c-Myc signaling
In order to elucidate the molecular mechanisms of siRNA-ZXF2 mediated suppression of migration and invasion, two key proteins were selected. One was c-Myc which is a strong Cellular Physiology and Biochemistry
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proto-oncogene promoting cancer cell migration and invasion [13] . The other was E-cadherin which is frequently lost during tumor progression and transition to a more motile and invasive phenotype [14] . Interestingly, bioinformatics analysis revealed that both ZXF2 and c-Myc are adjacently located on 8q24.2 loci of human chromosome 8, which is a "hot spot" for multiple human cancers [15] [16] [17] . The Western blot analysis showed that transfection of siRNA-ZXF2 suppressed c-myc and enhanced e-cadherin expression, indicating a potential role of ZXF2 on controlling lung cancer progression through c-myc/e-cadherin pathway ( Fig.  5G-5I ).
Discussion
It has been reported that 4%-9% of the transcription in mammalian genome are lncRNAs, whereas the rate of protein-coding RNA is only 1%. Over a long period of time, lncRNA was considered as a "noise" in genome transcription without any biological functions. However, recent studies have showed that lncRNAs participate in a lot of critical biological regulations, such as X-chromosome silence, genomic imprinting and chromatin modification, transcription activation, transcription interference and nuclear transport et al. [4] . In recent years, increasing evidences have linked lncRNA to various biological processes and diseases [18] . For example, HOTAIR, one of the first lncRNAs, was reported to be involved in the progression of breast cancer [6] . Our group previously identified a group of lncRNAs that were differentially expressed between lung cancer tissues and adjacent normal tissues derived from patients with lung adenocarcinomas [8] .
In the present study, we tested the functions of one of the novel lncRNAs, ZXF2 (located on chromosome 8, SEQ_ID:AA311918) in lung cancer progression. We found that expression of ZXF2 was increased in human lung cancer tissues, negatively correlated with post-surgery survival and positively correlated with lymph node metastasis of patients with lung cancers. We knockdowned ZXF2 in A549 cells, a metastatic lung cancer cell line, in order to explore the cellular and molecular mechanisms of potential tumor promoting function of ZXF2. We found that siRNA-ZXF2 treatment led to suppression of cell proliferation, migration and invasion, and G 0 /G 1 arrest through regulating c-myc/e-cadherin pathway.
As development of cancer is a result of orchestration of a multiple genes network, some traditional approaches that targets single gene might only have limited effect on controlling tumor growth. Given this background, LncRNAs, which play an important role in regulation of transcription and post-transcription processes, might be a better approach for developing effective means to treat cancers. In the present study, we observed a very interesting phenomenon that ZXF2 can regulate tumor progression by targeting c-myc/e-cadherin pathway. C-myc has been shown to negatively regulate e-cadherin through activating the transcription of microRNA-9 in breast cancer cells [19] , which was consistent with our observation. In addition, c-Myc can induce expression of Cyclin D1 to promote cell cycle progression in multiple systems [20, 21] , and functional interactions between c-Myc and cylclin D1 play a critical role in tumor initiation, progression and response to chemotherapy [22] . Therefore, we suspect that our observation that knockdown of ZXF2 led to down regulation of Cyclin D1 could also be c-Myc dependent. The potential molecular mechanisms underlying ZXF2 mediated regulation of c-myc could be summarized as following: First, given the fact that both human c-myc and ZXF2 are adjacently located on chromosome 8 (8q24.2), and some lncRNAs have been demonstrated to control myc expression through regulate long-range interactions between the MYC promoter and its enhancers in cancer cells [23, 24] , it is possible that ZXF2 functions as a transcriptional enhancer of MYC gene. Second, a recent elegant study show that lncRNA can directly bind and serve as a coactivator of c-Myc to activate transactivation functions of c-Myc [25] . Finally, lncRNA has been shown to regulate mRNA stability of c-Myc [26] . Further studies will confirm the mechanism involved in ZXF2 mediated regulation of c-Myc.
Conclusion
In conclusion, lncRNA ZXF2 was overexpressed in human lung adenocarcinoma. The high level of lncRNA ZXF2 was associated with lymph node metastasis and poor postoperative survival time. The overexpression of ZXF2 promoted proliferation, migration and invasion of cancer cell. The study revealed that ZXF2 might be an important marker in lung adenocarcinoma metastasis and might also be a therapeutic target in the treatment of lung adenocarcinoma.
